Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Izanne RoosCharles MalpasEmmanuelle LerayRomain CaseyDana HorakovaEva Kubala HavrdovaMarc DebouverieFrancesco PattiJerome De SezeGuillermo IzquierdoSara EichauGilles EdanAlexandre PratMarc GirardSerkan OzakbasPierre GrammondHelene ZephirJonathan CironElisabeth MaillartThibault MoreauMaria Pia AmatoPierre LabaugeRaed AlroughaniKatherine BuzzardOlga SkibinaMurat TerziDavid Axel LaplaudEric BergerFrancois Grand'MaisonChristine Lebrun-FrénayElisabetta CartechiniCavit BozJeannette Lechner-ScottPierre ClavelouBruno StankoffJulie PrevostLudwig KapposJean PelletierVahid ShaygannejadBassem I YamoutSamia J KhouryOliver GerlachDaniele L A SpitaleriVincent van PeschOlivier GoutRecai TurkogluOlivier HeinzlefEric ThouvenotPamela Ann McCombeAysun SoysalBertrand BourreMark SleeTamara Castillo TriviñoSerge BakchineRadek AmpapaErnest Gerard ButlerAbir WahabRichard A MacdonellEduardo AgüeraPhilippe CabreNasr Haifa BenAnneke Van Der WaltGuy LaureysLiesbeth Van HijfteCristina M Ramo-TelloNicolas MaubeugeSuzanne HodgkinsonJose Luis Sanchez-MenoyoMichael Harry BarnettCeline LabeyrieSteve VucicYoussef SidhomRiadh GouiderTünde CsépányJavier SotocaKoen de GansAbdullah Al-AsmiYara Dadalti FragosoSandra VukusicHelmut ButzkuevenTomas Kalinciknull nullPublished in: Neurology (2022)
This study provides Class III that disease reactivation occurs within months of discontinuation of MS disease-modifying therapies. The risk of disease activity is reduced by commencement of a subsequent therapy.